老年晚期非小细胞肺癌的靶向治疗  

Targeted therapy for elderly patients with non-small cell lung cancer

作　　者：张卉[1] 张树才[1] 

机构地区：[1]首都医科大学附属北京胸科医院肿瘤内科,101149

出　　处：《国际肿瘤学杂志》2012年第11期851-854,共4页Journal of International Oncology

摘　　要：老年肺癌发病及死亡呈上升趋势，但老年患者整体接受积极治疗的人数却明显少于非老年患者。随着分子靶向治疗药物，如人表皮生长因子受体酪氨酸激酶抑制剂、新生血管抑制剂、抗肿瘤单克隆抗体及多靶点药物的出现，老年晚期非小细胞肺癌患者的总生存时间得到显著延长，生活质量得到明显改善。靶向治疗已成为最有希望且能显著改善老年患者预后的治疗方法。In recent years, the incidence and mortality of advanced lung cancer in elderly patients have been increasing, but the number of elderly patients with lung cancer who receive active treatment is less than that of lung caner patients in other age stage. Molecular targeted therapies, such as the human epidermal growth factor receptor tyrosine kinase inhibitors, angiogenesis inhibitors, anti-tumor monoclonal antibodies and muhi- target drugs, have prolonged the overall survival and improved the life quality of elderly patients with advanced non-small cell lung cancer. Targeted therapy has become the most promising treatment and can significantly improve the prognosis of elderly patients.

关 键 词：老年人 癌 非小细胞肺 表皮生长因子 靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]